Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Patent
1995-06-07
1999-08-03
Weber, Jon P.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
514863, 514864, 435325, A61K 3107, C12N 506
Patent
active
059326220
ABSTRACT:
A method for modulating non-malignant skin related disorders in a subject has been demonstrated with 9-cis retinoic acid. Wrinkling, acne, keratinization, differentiation and proliferation disorders are treated by administration of 9-cis retinoic acid alone or in a pharmaceutically acceptable carrier to a subject in need thereof.
REFERENCES:
patent: 5192534 (1993-03-01), Grollier et al.
Mezick et al. (1984) J. Investigat. Dermatol., (83)2, "Topical and Systemic Effects of Retinoids on Horn-Filled Utriculus Size in the Rhino Mouse. A Model to Quantify `Antikeratinizing` Effects of Retinoids", pp. 110-113.
Brockes (1990) Nature, 345, "Reading the Retinoid Signals", pp. 766-768.
Lehmann et al. (1992) Science, 258, "Retinoids Selective for Retinoid X Receptor Response Pathways", pp. 1944-1946.
Levin et al. (1992) nature, 355, "9-Cis Retinoid Acid Stereoisomer Binds and Activates the Nuclear Receptor RXR.alpha.", pp. 359-361.
Boehm Marcus F.
Eichele Gregor
Evans Ronald M.
Heyman Richard A.
Mangelsdorf David J.
Baylor College of Medicine
Ligand Pharmaceuticals Inc.
Reiter Stephen E.
The Salk Institute for Biological Studies
Weber Jon P.
LandOfFree
Method for in vivo modulation of non-malignant skin-related proc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for in vivo modulation of non-malignant skin-related proc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for in vivo modulation of non-malignant skin-related proc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-849952